Founded in 2022, QuantX Biosciences applies high-performance computing, physics-based modeling, statistical methods, and computational chemistry to rapidly design and optimize oral small-molecule therapeutics. Its proprietary platform has already generated several first-in-class candidates, including best-in-class oral inhibitors of STAT6 and IL-17 that are moving toward clinical evaluation. The company is building a pipeline aimed at large patient populations across immunology and inflammation, with multiple programs now in IND-enabling studies. QuantX plans to use its latest funding to advance these lead assets into human trials while continuing to expand its discovery engine. The team, assembled in just three years, combines veteran drug hunters and computational scientists. Headquartered in Princeton, New Jersey, the privately held firm has raised $130 million since inception, reflecting strong investor confidence in its platform and pipeline.

Total raised

$85M

Funding rounds

1

Latest round

Series B

Latest activity

Feb 2026